Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRISBullishCorporate Developmentsnews

Medium materiality6/10

Curis Doses First Five CLL Patients in TakeAim Trial; Data Due December 2026

Jul 30, 2026, 8:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone-driven upside potential from an early-stage trial, particularly if data show deeper responses with a BTKi, can re-rate a small biotech like CRIS; however, the impact is tempered by small patient numbers and ongoing cash needs that could limit upside without funding.

AI summary

What happened, with direct paths to the underlying reporting

Curis has dosed the first five patients in its TakeAim CLL study, with initial data anticipated in December 2026. The emavusertib and zanubrutinib combination targets dual NF-kB pathways (BCR and TLR) to deepen responses and potentially enable fixed-duration therapy. Positive early signals could lift Curis valuation, but cash runway and near-term funding needs remain key risks.

Doses first five TakeAim CLL patients; initial data due Dec 2026.
Enrollment exceeds expectations: 11 sites opened, 10 patients consented.
Emavusertib + zanubrutinib aim to deepen NF-kB blockade in CLL.
Curis cites cash runway risk; needs funding to sustain operations.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Curis Doses First Five CLL Patients in TakeAim Trial; Data Due December 2026

Analyst raises CRIS PT to $43 on TakeAim CLL and timeline shifts

Curis updates boost PCNSL data and CLL enrollment, signaling regulatory optionality